Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
Open Access
- 8 May 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (5), 445
- https://doi.org/10.3390/ph14050445
Abstract
Antibiotic-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors. We investigated the impact of antibiotics on the clinical outcomes of nivolumab in patients with non-small cell lung cancer (NSCLC). Patients who received nivolumab for NSCLC between July 2015 and June 2018 and who were followed up until June 2020 were included in a retrospective cohort analysis. Of 140 eligible patients, 70 were on antibiotics. Overall survival (OS) was shorter in patients on antibiotics (ABX) compared to those not on antibiotics (NoABX) (p = 0.014). OS was negatively associated with piperacillin/tazobactam (PTZ) (HR = 3.31, 95% CI: 1.77–6.18), days of therapy (DOT) ≥ 2 weeks (HR = 2.56, 95% CI: 1.30–5.22) and DOT of PTZ. The defined daily dose (DDD) in PTZ (r = 0.27) and glycopeptides (r = 0.21) showed weak correlations with mortality. There was no difference in progression-free survival (PFS) between ABX and NoABX; however, PFS was negatively associated with the antibiotic class PTZ and DOT of PTZ. Therefore, the use of a broad-spectrum antibiotic, such as PTZ, the long-term use of antibiotics more than 2 weeks in total and the large amount of defined daily dose of specific antibiotics were associated with decreased survival in patients receiving nivolumab for NSCLC.Funding Information
- National Research Foundation of Korea (NRF) Grant Funded by the Korea Government Ministry of Science and ICT (2020R1A2C1009224, NRF-2020R1A6A1A03043528, 2017R1D1A1B03033389)
This publication has 41 references indexed in Scilit:
- Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in KoreaCancer Research and Treatment, 2020
- Interaction between microbiota and immunity in health and diseaseCell Research, 2020
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?Journal of Translational Medicine, 2018
- Evaluation of Nivolumab Use and Factors related to Treatment Outcomes in a Cancer Center of a Top Tier General HospitalKorean Journal of Clinical Pharmacy, 2018
- Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapyLung Cancer, 2018
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer ImmunotherapyCancer Cell, 2018
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancerAnnals of Oncology, 2018
- Immunotherapy in previously treated non-small cell lung cancer (NSCLC)Journal of Thoracic Disease, 2018
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience, 2018
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015